NVAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Novavax Inc (NVAX) is not a strong buy for a beginner, long-term investor at this time. While the company has shown revenue growth, its declining net income and EPS, coupled with a lack of strong technical or trading signals, suggest limited upside potential in the near term. The stock's recent analyst ratings and price targets also reflect mixed sentiment, with no clear consensus on significant growth.
The MACD is below 0 and negatively expanding (-0.2), indicating bearish momentum. RSI is at 26.101, suggesting the stock is near oversold territory but not yet signaling a reversal. Moving averages are converging, showing no clear trend. Key support is at 8.98, and resistance is at 10.652, with the stock trading near support levels.
The company has entered a licensing agreement with Pfizer, which could lead to high-margin revenue streams in the future. Revenue increased by 66.61% YoY in Q4 2025, and gross margin improved significantly to 84.98%.
Net income and EPS dropped significantly YoY (-121.63% and -121.57%, respectively). Analysts' ratings are mixed, with some maintaining underperform or sell ratings. Technical indicators suggest bearish momentum, and there are no significant hedge fund or insider trading trends.
In Q4 2025, revenue increased by 66.61% YoY to $147.1M, and gross margin improved to 84.98%. However, net income dropped to -$17.5M (-121.63% YoY), and EPS fell to 0.11 (-121.57% YoY), reflecting profitability challenges.
Analysts have mixed opinions. BofA and Citi maintain underperform and sell ratings with price targets of $8 and $7, respectively. H.C. Wainwright is more optimistic with a buy rating and a price target of $16. TD Cowen has a hold rating with a price target of $8.
